US-EU Index & Corporate Actions Analyst, ORTEX

Harry Kalfas

Index Rebalance professional with expertise in assessing the impact of Corporate Actions on major U.S., EU, and global indices. Specialized in forecasting index adjustments driven by Mergers & Acquisitions, Spin-offs, IPOs, and Equity Offerings, as well as analyzing shareholder structures and calculating free float. Assessed capital flows and capital invested in major equity indices. All forecasts and analyses are derived from publicly available, reliable sources, including exchange filings, regulatory disclosures, company announcements, and ETFs, without the use of index data. Producing forecasts for both scheduled and unscheduled index rebalances while providing insights into key aspects of Corporate Actions throughout their lifecycle.

US-EU Index & Corporate Actions Analyst

Cross-Border Merger of Akzo Nobel and Axalta Creating $25B Group: Big US and EU Index Flows Expected

Zurich-Beazley and Nuveen-Schroders Deals Near Completion, UK & European Index Replacements Ahead

Aptiv Spins Off Versigent: US and Global Index Implications Triggered

Keurig Dr Pepper’s €15.7B Deal for JDE Peet’s - Index Changes and a New Chapter for Coffee Strategy

Fifth Third to Acquire Comerica: Major US and Global Index Implications Triggered

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/boston-scientific-corp-7b5acbaf-edc4-4649-ac81-c71e7328f7bb" target="_blank" data-smartkarma-citation="entities:26842:1" rel="noopener">Boston Scientific (BSX UN)</a> is acquiring <a href="https://www.smartkarma.com/entities/penumbra-inc" target="_blank" data-smartkarma-citation="entities:26380:1" rel="noopener">Penumbra (PEN US)</a> in a cash-or-stock transaction valued at approximately $14.5B.</li>
<li>The transaction is expected to close later in 2026 (subject to approvals) with PEN shareholders receiving either $374 in cash or 3.8721 BSX shares per PEN share.</li>
<li>Upon completion, the deal will trigger significant passive inflows, with an upweight of <a href="https://www.smartkarma.com/entities/boston-scientific-corp-7b5acbaf-edc4-4649-ac81-c71e7328f7bb" target="_blank" data-smartkarma-citation="entities:26842:1" rel="noopener">Boston Scientific (BSX UN)</a> and the removal of <a href="https://www.smartkarma.com/entities/penumbra-inc" target="_blank" data-smartkarma-citation="entities:26380:1" rel="noopener">Penumbra (PEN US)</a> from relevant indices.</li>
</ul>



Boston Scientific (BSX UN) is acquiring Penumbra (PEN US) in a cash-or-stock transaction valued at approximately $14.5B.
The transaction is expected to close later in 2026 (subject to approvals) with PEN shareholders receiving either $374 in cash or 3.8721 BSX shares per PEN share.
Upon completion, the deal will trigger significant passive inflows, with an upweight of Boston Scientific (BSX UN) and the removal of Penumbra (PEN US) from relevant indices.


Boston Scientific to Acquire Penumbra: $14.5B Deal Triggering Significant Index Flows